What is Kezar Life Sciences, Inc.'s earnings per share (EPS)?

Kezar Life Sciences, Inc. (KZR) reported diluted earnings per share of -$7.66 for fiscal year 2025. This represents a 33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kezar Life Sciences, Inc. (KZR) Financials

KZR

FY2025 annual

Revenue $0 YoY not available

Net Income -$56.0M +33.1% YoY

EPS (Diluted) -$7.66 +33.3% YoY

Free Cash Flow -$51.8M +30.2% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 11, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KZR SEC filings page.

Kezar Life Sciences, Inc. (KZR) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KZR FY2025 2026-08-29

Development-stage operations consume cash through R&D while revenue remains too small to fund the operating model.

In FY2023, R&D spending reached $85.7M against $7.0M of revenue, while operating cash flow was -$81.6M; cash use therefore tracked development investment rather than a sales-funded operating base.

The FY2023 balance sheet was lightly debt-funded: liabilities were $33.7M against assets of $221.2M, with debt-to-equity at 0.1x. The reported financial pressure therefore came primarily from operating cash consumption, not interest-bearing leverage.

Some figures from recent filings were inconsistent and were omitted from this summary.

Financial Health Signals

Financial health score pending refresh

We are recalculating Kezar Life Sciences, Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-5.51

Kezar Life Sciences, Inc. scores -5.51, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($53.9M) relative to total liabilities ($6.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Kezar Life Sciences, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Kezar Life Sciences, Inc. reported a net loss of $56.0M while operations used $51.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$7.3M

YoY+57.9%

Kezar Life Sciences, Inc.'s EBITDA was -$7.3M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 57.9% from the same quarter a year earlier.

Net Income

-$5.8M

YoY+65.2%

Kezar Life Sciences, Inc. reported -$5.8M in net income in Q1 2026. This represents an increase of 65.2% from the same quarter a year earlier.

EPS (Diluted)

-$0.78

YoY+65.6%

QoQ+60.8%

Kezar Life Sciences, Inc. earned -$0.78 per diluted share (EPS) in Q1 2026. This represents an increase of 65.6% from the same quarter a year earlier. Against the prior quarter it is up 60.8%.

Revenue

Not reported for Q1 2026.

Cash & Balance Sheet

Free Cash Flow

-$7.4M

YoY+56.7%

QoQ+37.8%

Kezar Life Sciences, Inc. recorded an outflow of $7.4M in free cash flow in Q1 2026, representing a cash shortfall after capex. This represents an increase of 56.7% from the same quarter a year earlier. Against the prior quarter it is up 37.8%.

Cash & Debt

$66.2M

YoY+79.0%

QoQ-7.9%

5Y CAGR+23.7%

Kezar Life Sciences, Inc. held $66.2M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+1.1%

QoQ+0.2%

5Y CAGR-31.2%

Kezar Life Sciences, Inc. had 7M shares outstanding in Q1 2026. This represents an increase of 1.1% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

-8.8%

YoY+7.2pp

Kezar Life Sciences, Inc.'s ROE was -8.8% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 7.2 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$1.5M

YoY-87.3%

Kezar Life Sciences, Inc. invested $1.5M in research and development in Q1 2026. This represents a decrease of 87.3% from the same quarter a year earlier.

Capital Expenditures

YoY-100.0%

Kezar Life Sciences, Inc. reported no capital expenditure in Q1 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

KZR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KZR quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	N/A	$0	$0-100.0%	$7.0M	$0	$0	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$33.8M-48.7%	$65.7M-23.3%	$85.7M+68.0%	$51.0M+31.0%	$38.9M+25.7%	$31.0M+13.2%	$27.4M+50.9%	$18.1M+180.4%	$6.5M-12.3%	$7.4M
SG&A Expenses	N/A	$18.5M-20.9%	$23.4M-11.9%	$26.5M+31.7%	$20.2M+28.2%	$15.7M+31.4%	$12.0M+19.9%	$10.0M+51.4%	$6.6M+189.0%	$2.3M+41.0%	$1.6M
Operating Income	N/A	-$59.1M+34.8%	-$90.6M+18.7%	-$111.4M-56.6%	-$71.2M-30.2%	-$54.7M-27.3%	-$43.0M-15.0%	-$37.3M-51.0%	-$24.7M-182.6%	-$8.7M+2.7%	-$9.0M
EBITDA	N/A	-$58.2M+35.0%	-$89.6M+18.8%	-$110.4M-57.3%	-$70.1M-32.0%	-$53.1M-28.4%	-$41.4M-14.9%	-$36.0M-49.9%	-$24.0M-180.3%	-$8.6M+3.0%	-$8.8M
Interest Expense	N/A	N/A	$1.6M+2.8%	$1.6M+30.8%	$1.2M+645.3%	$159K	$0	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$56.0M+33.1%	-$83.7M+17.8%	-$101.9M-49.3%	-$68.2M-24.9%	-$54.6M-30.9%	-$41.7M-19.0%	-$35.1M-51.5%	-$23.2M-172.0%	-$8.5M+5.3%	-$9.0M
EPS (Basic)	N/A	-$7.66+33.3%	-$11.49+18.2%	-$14.04-38.6%	-$10.13-874.0%	-$1.04-9.5%	-$0.95	N/A	N/A	N/A	N/A
EPS (Diluted)	-$6.17	-$7.66+33.3%	-$11.49	-$14.04-38.6%	-$10.13	-$1.04-9.5%	-$0.95	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	7M+0.4%	7M	7M+7.7%	7M	53M+19.9%	44M+130.6%	19M	10M	599,291+77.1%	338,446

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	N/A
R&D Expenses	$1.5M-87.3%	N/A	$6.9M-57.4%	$9.6M-41.2%	$12.2M-29.1%	N/A	$16.2M-31.6%	$16.3M-22.4%
SG&A Expenses	$5.2M-4.4%	N/A	$4.8M-15.9%	$5.0M-10.5%	$5.4M-16.7%	N/A	$5.7M-35.1%	$5.6M-3.1%
Operating Income	-$7.4M+58.2%	N/A	-$11.7M+46.6%	-$14.6M+37.6%	-$17.6M+25.7%	N/A	-$21.9M+14.0%	-$23.4M+12.7%
EBITDA	-$7.3M+57.9%	N/A	-$11.5M+46.8%	-$14.4M+37.6%	-$17.4M+25.9%	N/A	-$21.6M+14.2%	-$23.1M+13.2%
Interest Expense	$0-100.0%	N/A	N/A	$302K-24.7%	$347K-13.3%	N/A	$403K+1.8%	$401K+4.2%
Income Tax	$0	N/A	$0	$0	$0	N/A	$0	$0
Net Income	-$5.8M+65.2%	N/A	-$11.2M+44.7%	-$13.7M+36.4%	-$16.6M+23.6%	N/A	-$20.3M+12.1%	-$21.5M+11.4%
EPS (Basic)	-$0.78+65.6%	-$1.99+28.2%	-$1.53+45.0%	-$1.87+36.8%	-$2.27+23.8%	-$2.77-529.5%	-$2.78+12.6%	-$2.96-770.6%
EPS (Diluted)	-$0.78+65.6%	-$1.99+28.2%	-$1.53+45.0%	-$1.87	-$2.27	-$2.77	-$2.78	-$2.96
Diluted Shares (Avg)	7M+0.5%	N/A	7M+0.4%	7M	7M	N/A	7M	7M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

KZR Balance Sheet

KZR quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$76.6M-47.0%	$144.7M-34.6%	$221.2M-26.1%	$299.6M+37.5%	$217.9M+43.5%	$151.8M+69.6%	$89.5M-21.9%	$114.7M+111.5%	$54.2M	N/A
Current Assets	$75.7M-44.9%	$137.5M-33.6%	$206.9M-27.6%	$285.7M+35.0%	$211.7M+46.2%	$144.8M+78.5%	$81.1M-26.1%	$109.8M+109.8%	$52.3M	N/A
Cash & Equivalents	$71.9M+72.2%	$41.7M+17.6%	$35.5M-12.3%	$40.5M-35.7%	$62.9M+196.2%	$21.2M+42.0%	$15.0M-38.2%	$24.2M-52.6%	$51.0M+423.6%	$9.7M
Short-Term Investments	$0-100.0%	$90.5M-45.4%	$165.9M-29.7%	$236.1M+62.3%	$145.5M+22.0%	$119.2M+88.5%	$63.3M-24.0%	$83.3M	$0	$0
Accounts Receivable	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$6.6M-76.3%	$27.8M-17.5%	$33.7M+13.4%	$29.7M+41.0%	$21.1M+93.8%	$10.9M-5.3%	$11.5M+94.9%	$5.9M-92.6%	$79.9M	N/A
Current Liabilities	$6.6M-67.7%	$20.3M+14.6%	$17.7M+61.4%	$11.0M+33.9%	$8.2M+27.5%	$6.4M+7.3%	$6.0M+79.9%	$3.3M+124.9%	$1.5M	N/A
Non-Current Liabilities	$0-100.0%	$7.4M-53.3%	$15.9M-14.9%	$18.7M+45.6%	$12.8M+190.5%	$4.4M-19.1%	$5.5M+114.4%	$2.5M-96.8%	$78.4M	N/A
Long-Term Debt	$0-100.0%	$5.1M-49.2%	$10.1M+2.4%	$9.8M+2.2%	$9.6M	N/A	N/A	N/A	N/A	N/A
Total Equity	$70.1M-40.1%	$116.9M-37.7%	$187.6M-30.5%	$269.9M+37.1%	$196.9M+39.7%	$141.0M+80.6%	$78.0M-28.3%	$108.8M+523.5%	-$25.7M-47.4%	-$17.4M
Retained Earnings	-$490.5M-12.9%	-$434.5M-23.9%	-$350.8M-40.9%	-$248.9M-37.8%	-$180.7M-43.3%	-$126.0M-49.5%	-$84.3M-71.3%	-$49.2M-89.0%	-$26.0M	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$68.0M-45.7%	$76.6M-47.0%	$97.7M-40.4%	$109.1M-39.3%	$125.3M-37.1%	$144.7M-34.6%	$164.1M-34.2%	$179.9M-31.7%
Current Assets	$67.6M-43.8%	$75.7M-44.9%	$94.5M-39.6%	$104.7M-37.5%	$120.3M-35.2%	$137.5M-33.6%	$156.4M-32.2%	$167.6M-31.2%
Cash & Equivalents	$66.2M+79.0%	$71.9M+72.2%	$38.9M+11.7%	$34.4M+21.5%	$37.0M+12.0%	$41.7M+17.6%	$34.9M+31.5%	$28.3M+0.6%
Short-Term Investments	$0-100.0%	$0-100.0%	$51.3M-54.8%	$66.5M-51.1%	$77.4M-47.3%	$90.5M-45.4%	$113.5M-40.8%	$135.9M-34.8%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.8M-87.6%	$6.6M-76.3%	$14.8M-50.9%	$17.3M-40.7%	$22.2M-26.1%	$27.8M-17.5%	$30.0M-9.9%	$29.2M-6.0%
Current Liabilities	$2.8M-83.7%	$6.6M-67.7%	$13.4M-34.5%	$14.4M-17.9%	$17.0M+5.0%	$20.3M+14.6%	$20.4M+22.5%	$17.5M+27.4%
Non-Current Liabilities	$0-100.0%	$0-100.0%	$1.4M-85.7%	$3.0M-74.7%	$5.2M-62.2%	$7.4M-53.3%	$9.6M-42.3%	$11.7M-32.4%
Long-Term Debt	N/A	$0-100.0%	$1.4M-78.4%	$2.6M-65.4%	$3.9M-56.1%	$5.1M-49.2%	$6.3M-36.6%	$7.6M-23.7%
Total Equity	$65.2M-36.7%	$70.1M-40.1%	$83.0M-38.1%	$91.8M-39.1%	$103.1M-39.1%	$116.9M-37.7%	$134.0M-37.9%	$150.7M-35.1%
Retained Earnings	-$496.3M-10.0%	-$490.5M-12.9%	-$476.0M-14.9%	-$464.8M-18.0%	-$451.1M-21.1%	-$434.5M-23.9%	-$414.3M-30.1%	-$394.0M-33.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

KZR Cash Flow Statement

KZR quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$42.0M	-$51.8M+30.2%	-$74.2M+9.1%	-$81.6M-38.7%	-$58.8M-38.7%	-$42.4M-14.9%	-$36.9M-23.7%	-$29.9M-43.7%	-$20.8M-156.4%	-$8.1M+16.9%	-$9.8M
Depreciation & Amortization	N/A	$897K-13.8%	$1.0M-2.4%	$1.1M+4.2%	$1.0M-32.3%	$1.5M-2.2%	$1.5M+18.7%	$1.3M+88.6%	$690K+294.3%	$175K+13.6%	$154K
Stock-Based Compensation	N/A	$9.0M-31.1%	$13.0M-28.3%	$18.1M+29.5%	$14.0M+84.4%	$7.6M+53.7%	$4.9M+23.4%	$4.0M+101.1%	$2.0M+881.8%	$203K+58.6%	$128K
Capital Expenditures	$0	$8K-72.4%	$29K-98.4%	$1.8M+14.7%	$1.6M+399.4%	$316K+62.9%	$194K-68.0%	$607K-45.8%	$1.1M+187.9%	$389K+194.7%	$132K
Free Cash Flow	-$42.0M	-$51.8M+30.2%	-$74.2M+11.0%	-$83.5M-38.1%	-$60.4M-41.3%	-$42.8M-15.1%	-$37.1M-21.8%	-$30.5M-39.1%	-$21.9M-157.8%	-$8.5M+14.1%	-$9.9M
Investing Cash Flow	$80.3M	$92.5M+15.0%	$80.4M+5.8%	$76.0M+183.2%	-$91.4M-221.3%	-$28.4M+49.7%	-$56.5M-376.7%	$20.4M+124.3%	-$83.9M-21469.2%	-$389K-194.7%	-$132K
Financing Cash Flow	-$9.0M	-$10.6M-10376.7%	$103K-83.9%	$638K-99.5%	$127.9M+13.6%	$112.6M+13.0%	$99.6M+36533.1%	$272K-99.7%	$77.9M+56.6%	$49.8M+138108.3%	$36K
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$7.4M+56.7%	-$12.0M+28.9%	-$9.8M+43.8%	-$12.8M+24.9%	-$17.2M+24.8%	-$16.8M+11.4%	-$17.5M+13.4%	-$17.0M+21.2%
Depreciation & Amortization	$47K-81.3%	$176K-32.0%	$200K-33.3%	$200K-33.3%	$251K-3.5%	$259K-7.5%	$300K0.0%	$300K+50.0%
Stock-Based Compensation	$653K-76.5%	N/A	$2.1M-32.9%	$2.4M-21.5%	$2.8M-19.1%	N/A	$3.2M-52.0%	$3.1M-23.3%
Capital Expenditures	$0-100.0%	$0-100.0%	$0-100.0%	$0	$8K	$11K+1000.0%	$18K-86.8%	$0-100.0%
Free Cash Flow	-$7.4M+56.7%	-$12.0M+28.9%	-$9.8M+43.9%	-$12.8M+24.9%	-$17.2M+24.8%	-$16.8M+11.3%	-$17.5M+13.9%	-$17.0M+25.9%
Investing Cash Flow	$1.5M-88.9%	$51.6M+117.4%	$15.7M-34.7%	$11.4M-6.7%	$13.7M-32.7%	$23.7M-14.8%	$24.1M+29.5%	$12.2M-7.5%
Financing Cash Flow	$267K+120.5%	-$6.7M-14370.2%	-$1.3M	-$1.3M-2366.1%	-$1.3M	$47K-20.3%	$0-100.0%	$56K-85.3%
Dividends Paid	$0	$0	$0	$0	$0	$0	$0	$0

Not reported in any period shown, so not listed: Share Buybacks.

KZR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KZR quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Margin	N/A	N/A	-1591.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	-1455.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-80.0%-8.3pp	-71.6%-17.3pp	-54.3%-29.0pp	-25.3%+2.5pp	-27.8%+1.9pp	-29.6%+15.4pp	-45.0%-23.7pp	-21.3%	N/A	N/A
Return on Assets	-73.1%-15.2pp	-57.9%-11.8pp	-46.1%-23.3pp	-22.8%+2.3pp	-25.1%+2.4pp	-27.5%+11.7pp	-39.2%-19.0pp	-20.2%-4.5pp	-15.7%	N/A
Current Ratio	11.52+4.8x	6.76-4.9x	11.66-14.3x	25.98+0.2x	25.77+3.3x	22.48+9.0x	13.52-19.4x	32.91-2.4x	35.26	N/A
Debt-to-Equity	0.000.0x	0.040.0x	0.050.0x	0.040.0x	0.050.0x	0.08-0.1x	0.15+0.1x	0.05	N/A	N/A
Asset Turnover	0.000.0x	0.000.0x	0.030.0x	0.000.0x	0.00	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	-1192.2%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Return on Equity	-8.8%+7.2pp	N/A	-13.5%+1.6pp	-14.9%-0.6pp	-16.1%-3.3pp	N/A	-15.2%-4.5pp	-14.3%-3.8pp
Return on Assets	-8.5%+4.8pp	N/A	-11.5%+0.9pp	-12.6%-0.6pp	-13.2%-2.3pp	N/A	-12.4%-3.1pp	-12.0%-2.8pp
Current Ratio	24.46+17.4x	11.52+4.8x	7.07-0.6x	7.29-2.3x	7.09-4.4x	6.76-4.9x	7.65-6.2x	9.58-8.1x
Debt-to-Equity	0.040.0x	0.000.0x	0.020.0x	0.030.0x	0.040.0x	0.040.0x	0.050.0x	0.050.0x
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.000.0x	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Kezar Life Sciences, Inc. KZR	FY2025	$0	-$56.0M	N/A	$53.9M	—
Tenax Therapeutics, Inc. TENX	FY2025	$0	-$52.6M	N/A	$69.6M	—
Akari Therapeutics plc ADR (0.01 USD) AKTX	FY2025	N/A	-$17.3M	N/A	$22.0M	—
REVIVA PHARMA HLDGS INC RVPH	FY2025	N/A	-$19.9M	N/A	$10.2M	—
Allarity Therapeutics, Inc. ALLR	FY2025	$320K	-$11.2M	N/A	$19.4M	—
Sonnet BioTherapeutics Holdings, Inc. SONN	FY2025	$1.0M	-$16.0M	N/A	$8.6M	69/100

Where Kezar Life Sciences, Inc. Ranks

Frequently Asked Questions

What is Kezar Life Sciences, Inc.'s annual revenue?

Kezar Life Sciences, Inc. (KZR) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Kezar Life Sciences, Inc. profitable?

No, Kezar Life Sciences, Inc. (KZR) reported a net income of -$56.0M in fiscal year 2025.

What is Kezar Life Sciences, Inc.'s EBITDA?

Kezar Life Sciences, Inc. (KZR) had EBITDA of -$58.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Kezar Life Sciences, Inc. have?

As of fiscal year 2025, Kezar Life Sciences, Inc. (KZR) had $71.9M in cash and equivalents against $0 in long-term debt.

What is Kezar Life Sciences, Inc.'s return on equity (ROE)?

Kezar Life Sciences, Inc. (KZR) has a return on equity of -80.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Kezar Life Sciences, Inc.'s free cash flow?

Kezar Life Sciences, Inc. (KZR) recorded an outflow of $51.8M in free cash flow during fiscal year 2025. This represents a 30.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kezar Life Sciences, Inc.'s operating cash flow?

Kezar Life Sciences, Inc. (KZR) recorded an outflow of $51.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Kezar Life Sciences, Inc.'s total assets?

Kezar Life Sciences, Inc. (KZR) had $76.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Kezar Life Sciences, Inc.'s capital expenditures?

Kezar Life Sciences, Inc. (KZR) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Kezar Life Sciences, Inc. spend on research and development?

Kezar Life Sciences, Inc. (KZR) invested $33.8M in research and development during fiscal year 2025.

How many shares does Kezar Life Sciences, Inc. have outstanding?

Kezar Life Sciences, Inc. (KZR) had 7M shares outstanding as of fiscal year 2025.

What is Kezar Life Sciences, Inc.'s current ratio?

Kezar Life Sciences, Inc. (KZR) had a current ratio of 11.52 as of fiscal year 2025, which is generally considered healthy.

What is Kezar Life Sciences, Inc.'s debt-to-equity ratio?

Kezar Life Sciences, Inc. (KZR) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kezar Life Sciences, Inc.'s return on assets (ROA)?

Kezar Life Sciences, Inc. (KZR) had a return on assets of -73.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Kezar Life Sciences, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Kezar Life Sciences, Inc. (KZR) held $71.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $51.8M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Kezar Life Sciences, Inc.'s Altman Z-Score?

Kezar Life Sciences, Inc. (KZR) has an Altman Z-Score of -5.51, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Kezar Life Sciences, Inc.'s Piotroski F-Score?

Kezar Life Sciences, Inc. (KZR) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kezar Life Sciences, Inc.'s earnings high quality?

Kezar Life Sciences, Inc. (KZR) reported a net loss of $56.0M while operations used $51.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.